Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease
- PMID: 15451225
- DOI: 10.1016/S0140-6736(04)17104-3
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease
Abstract
The alpha-synuclein gene (SNCA) has been implicated in autosomal dominant forms of Parkinson's disease. We screened 119 individuals from families with this rare form of the disease for SNCA duplications by semiquantitative multiplex PCR. Two patients had duplications, which were confirmed by analysis of intragenic and flanking microsatellite markers. The phenotype in both patients was indistinguishable from idiopathic Parkinson's disease and no atypical features were present, by contrast with reports of families with triplication of the same gene. These results indicate that SNCA is more frequently associated with familial Parkinson's disease than previously thought, and that there is a clear dosage effect according to the number of supernumerary copies of this gene.
Comment in
-
Parkinson's disease and dementia with Lewy bodies: a difference in dose?Lancet. 2004 Sep 25-Oct 1;364(9440):1105-7. doi: 10.1016/S0140-6736(04)17117-1. Lancet. 2004. PMID: 15451205 No abstract available.
Similar articles
-
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9. doi: 10.1016/S0140-6736(04)17103-1. Lancet. 2004. PMID: 15451224
-
Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease.Neurosci Lett. 2004 Aug 26;367(1):97-100. doi: 10.1016/j.neulet.2004.05.100. Neurosci Lett. 2004. PMID: 15308306
-
Gene dosage and pathogenesis of Parkinson's disease.Trends Mol Med. 2005 Mar;11(3):91-6. doi: 10.1016/j.molmed.2005.01.001. Trends Mol Med. 2005. PMID: 15760766 Review.
-
Parkinson's disease and dementia with Lewy bodies: a difference in dose?Lancet. 2004 Sep 25-Oct 1;364(9440):1105-7. doi: 10.1016/S0140-6736(04)17117-1. Lancet. 2004. PMID: 15451205 No abstract available.
-
[Relationship between alpha-synuclein and Parkinson's disease].Brain Nerve. 2007 Aug;59(8):825-30. Brain Nerve. 2007. PMID: 17713118 Review. Japanese.
Cited by
-
α-Synuclein oligomers with broken helical conformation form lipoprotein nanoparticles.J Biol Chem. 2013 Jun 14;288(24):17620-30. doi: 10.1074/jbc.M113.476697. Epub 2013 Apr 22. J Biol Chem. 2013. PMID: 23609437 Free PMC article.
-
Definition of a molecular pathway mediating α-synuclein neurotoxicity.J Neurosci. 2015 Apr 1;35(13):5221-32. doi: 10.1523/JNEUROSCI.4650-14.2015. J Neurosci. 2015. PMID: 25834048 Free PMC article.
-
Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities.J Neurosci. 2012 Oct 24;32(43):15227-42. doi: 10.1523/JNEUROSCI.3545-12.2012. J Neurosci. 2012. PMID: 23100443 Free PMC article.
-
Advances in the genetics of Parkinson disease.Nat Rev Neurol. 2013 Aug;9(8):445-54. doi: 10.1038/nrneurol.2013.132. Epub 2013 Jul 16. Nat Rev Neurol. 2013. PMID: 23857047 Review.
-
Alpha-synuclein aggresomes inhibit ciliogenesis and multiple functions of the centrosome.Biol Open. 2020 Oct 5;9(10):bio054338. doi: 10.1242/bio.054338. Biol Open. 2020. PMID: 32878882 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous